Covalon Technologies Ltd. (CVALF)
OTCMKTS
· Delayed Price · Currency is USD
1.702
-0.040 (-2.32%)
Jun 13, 2025, 1:20 PM EDT
Covalon Technologies Revenue
Covalon Technologies had revenue of 7.59M CAD in the quarter ending March 31, 2025, a decrease of -9.84%. This brings the company's revenue in the last twelve months to 33.84M, up 28.97% year-over-year. In the fiscal year ending September 30, 2024, Covalon Technologies had annual revenue of 31.17M with 17.20% growth.
Revenue (ttm)
33.84M CAD
Revenue Growth
+28.97%
P/S Ratio
2.00
Revenue / Employee
914.70K CAD
Employees
37
Market Cap
47.04M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 31.17M | 4.57M | 17.20% |
Sep 30, 2023 | 26.60M | 8.45M | 46.56% |
Sep 30, 2022 | 18.15M | -1.41M | -7.23% |
Sep 30, 2021 | 19.56M | 6.05M | 44.81% |
Sep 30, 2020 | 13.51M | -20.50M | -60.27% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Covalon Technologies News
- 16 days ago - Covalon Technologies Ltd. (CVALF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Covalon Technologies GAAP EPS of $0.02, revenue of $7.59M beats by $2.2M - Seeking Alpha
- 17 days ago - Covalon Reports Fifth Consecutive Quarter of Positive Earnings - Financial Post
- 17 days ago - Covalon Reports Fifth Consecutive Quarter of Positive Earnings - Business Wire
- 18 days ago - Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard - Financial Post
- 18 days ago - Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard - Business Wire
- 24 days ago - Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2025 Financial Results - Business Wire
- 25 days ago - Covalon Retains Financial and Strategic Advisor to Advise on Shareholder Value-Enhancing Opportunities - Business Wire